全文获取类型
收费全文 | 1039篇 |
免费 | 32篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 63篇 |
妇产科学 | 45篇 |
基础医学 | 130篇 |
口腔科学 | 6篇 |
临床医学 | 79篇 |
内科学 | 162篇 |
皮肤病学 | 14篇 |
神经病学 | 73篇 |
特种医学 | 56篇 |
外科学 | 168篇 |
综合类 | 2篇 |
预防医学 | 64篇 |
眼科学 | 10篇 |
药学 | 40篇 |
肿瘤学 | 142篇 |
出版年
2023年 | 5篇 |
2021年 | 20篇 |
2020年 | 16篇 |
2019年 | 11篇 |
2018年 | 21篇 |
2017年 | 9篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 18篇 |
2012年 | 32篇 |
2011年 | 46篇 |
2010年 | 12篇 |
2009年 | 19篇 |
2008年 | 46篇 |
2007年 | 58篇 |
2006年 | 57篇 |
2005年 | 72篇 |
2004年 | 44篇 |
2003年 | 43篇 |
2002年 | 31篇 |
2001年 | 32篇 |
2000年 | 31篇 |
1999年 | 40篇 |
1998年 | 14篇 |
1997年 | 14篇 |
1996年 | 10篇 |
1995年 | 13篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 24篇 |
1991年 | 25篇 |
1990年 | 22篇 |
1989年 | 33篇 |
1988年 | 31篇 |
1987年 | 34篇 |
1986年 | 25篇 |
1985年 | 12篇 |
1984年 | 10篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1974年 | 5篇 |
1973年 | 11篇 |
1972年 | 9篇 |
1971年 | 9篇 |
1970年 | 6篇 |
1967年 | 4篇 |
排序方式: 共有1072条查询结果,搜索用时 0 毫秒
51.
52.
Millan MJ Newman-Tancredi A Audinot V Cussac D Lejeune F Nicolas JP Cogé F Galizzi JP Boutin JA Rivet JM Dekeyne A Gobert A 《Synapse (New York, N.Y.)》2000,35(2):79-95
Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats. Yohimbine displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors. In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites. In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635-reversible induction of hypothermia in the rat. In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611. In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs. While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT. Further, yohimbine decreases firing of serotonergic neurones in raphe nuclei, an action reversed by WAY100,635. Fluparoxan increases extracellular levels of DA and NAD, but not 5-HT, in frontal cortex. In analogy, yohimbine enhances FCX levels of DA and NAD, yet suppresses those of 5-HT, the latter effect being antagonized by WAY100,635. The induction by fluoxetine of FCX levels of 5-HT, DA, and NAD is potentiated by fluparoxan. Yohimbine likewise facilitates the influence of fluoxetine upon DA and NAD levels, but not those of 5-HT. In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine. However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels. 相似文献
53.
D. Christoforidis O. Martinet F. J. Lejeune F. Mosimann 《European journal of surgical oncology》2002,28(8):875-890
Many treatments have been proposed for non-resectable primary or secondary hepatic cancer but the results have generally been disappointing. Isolated Hepatic Perfusion (IHP) was first attempted four decades ago but it gained acceptance only recently, after spectacular tumour responses were obtained by isolated limb perfusion with melphalan and tumour necrosis factor (TNF) for melanomas and sarcomas. Surgical isolation of the liver is a technically demanding operation that allows the safe administration of high doses of chemotherapeutics and TNF. Percutaneous techniques using balloon occlusion catheters are simpler but result in higher leakage rates from the perfusion circuit into the systemic circulation. Several phase I-II trials indicate that IHP can yield high tumour response rates, even when there is resistance to systemic chemotherapy. However, no significant advantage in overall survival has been demonstrated so far. IHP offers unique pharmacokinetic advantages for locoregional chemotherapy and biotherapy. It might also allow gene therapy with limited systemic exposure and toxicity. At present, IHP nevertheless remains an experimental treatment modality which should therefore be used in controlled trials only. 相似文献
54.
55.
56.
57.
58.
59.
60.